Skip to content
Screener

Immunome IMNM Acquired in-process research and development

Acquired in-process research and development at other companies

Gilead Sciences logo
Gilead SciencesGILD
$539M—

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.92B+221%
Enterprise value$2.35B+204%
P/S728.3×+656×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0×0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The source filing: Immunome’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219425
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating lease liabilities(161)(62)
Net cash used in operating activities(58,638)(53,055)
Cash flows from investing activities:
Purchases of in-process research and development assets(9,014)(6,246)
Purchases of property and equipment(3,002)(3,665)
Maturities of marketable securities—15,000
Net cash (used in) provided by investing activities(12,016)5,089
Cash flows from financing activities:

Item 1. Financial Statements.

FAQ

What is Immunome's acquired in-process research and development?
Immunome (IMNM) reported acquired in-process research and development of $9.01M in Q1 2026.
How has Immunome's acquired in-process research and development changed year-over-year?
Immunome's acquired in-process research and development increased by 44.3% year-over-year, from $6.25M to $9.01M.
What does acquired in-process research and development mean?
This represents the actual cash outflow associated with the acquisition of in-process research and development assets from third parties. Unlike non-cash charges, this metric tracks the deployment of capital to secure external innovation pipelines. It is a critical indicator of a company's strategy to supplement internal R&D with external intellectual property.

Ask your AI about Immunome's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude